Author:
Owyang Clark G.,Murali Shyam
Abstract
Abstract
Among the many complications of oncologic patients in acute care medicine are the metabolic and hematologic derangements of tumor lysis syndrome, hyperviscosity syndrome, and disseminated intravascular coagulation. While laboratory values are key characteristics in these disorders, clinical presentation drives the diagnostic and therapeutic workup. Disseminated intravascular coagulation is often marked by dramatic coagulopathy treated with supportive care, blood product replacement, and treatment of the precipitating event. Hyperviscosity syndrome may present variably often with neurologic or pulmonary complications and is treated with cytoreductive therapies of hydroxyurea, plasmapheresis, or chemotherapy. Finally, tumor lysis syndrome reflects purine breakdown sequelae, with rasburicase and renal support often utilized in therapy.
Publisher
Oxford University PressNew York
Reference20 articles.
1. How I treat hyperleukocytosis in acute myeloid leukemia.;Blood,2015
2. What’s new in the diagnostic criteria of disseminated intravascular coagulation?;Intensive Care Med,2016
3. Disseminated intravascular coagulation in cancer: An update.;Semin Thromb Hemost,2019
4. The scoring system of the Scientific and Standardisation Committee on Disseminated Intravascular Coagulation of the International Society on Thrombosis and Haemostasis: A 5-year overview.;J Thromb Haemost,2007
5. 5. DeLoughery TG. Disseminated intravascular coagulation. In: DeLoughery TG, ed. Hemostasis and Thrombosis. Springer International Publishing; 2019:55–59.